The consistently positive newsflow of Abivax in 2019 is finally rewarded by investors in the form of rising stock prices. Additional tailwind is provided by an ultra-bullish analyst commentary by Bryan Garnier.

According to analyst Eric Le Berrigaud, Abivax will be one of the "hottest topics in the biotech space" in 2020. The company is very likely to consider selling or partnering its anti-inflammatory drug ABX464. Le Berrigaud classifies the biotech share as "Strong Buy" with a price target of € 37.50. Current price: € 12.90. This is quite a statement!

The analyst brings as a potential dealmaker the Humira seller AbbVie, Johnson & Johnson, Sanofi and the Belgian biotech company Galapagos into play.

Positive Newsflow

Recently, the biotech company received the approval of the French authorities (ANSM) to include French study centers in the Phase 2b study for the treatment of ulcerative colitis with ABX464 the great hope of molecule of Abivax. Thus, the study can now be carried out in a total of 15 countries. And Abivax continues to drive the development of the drug in other exciting indications as well: Patient enrollment is currently underway for the Phase 2 clinical trial of ABX464 for the treatment of rheumatoid arthritis. The company is currently in preparation for their Phase 2a study in Crohn's disease.
DER AKTIONÄR recommended the Abivax share with a Buy for speculative investors in Issue 24/2019 in the section "Parquet Whispers" (Parkettgeflüster). Patience is now rewarded: In the meantime, the shares are around 45 percent above the target price of € 9.00. Increase Stop-Loss limit to € 9.30!